Clinical trials: Conjunctivitis
Seasonal Allergic Conjunctivitis
Alrex® Versus Patanol in the Treatment of Seasonal Allergic Conjunctivitis(SAC)
This study is to evaluate the safety and efficacy of Alrex (LE ophthalmic suspension, 0.2%) versus Patanol (olopatadine hydrochloride ophthalmic solution, 0.1%) in the temporary relief of the signs and symptoms of Seasonal…
- Trial name
- NCT01435460
- Testing
- Loteprednol etabonate 0.2%, Olopatadine 0.1%
- Where
- Singapore
- Volunteers
- 300 people
- Sponsor
- Bausch & Lomb Incorporated
KERATOCONJUNCTIVITIS SICCA, XEROSTOMIA
Laser Therapy to Treat the Dry Mouth of Sjogren's Syndrome
This study was designed to test the efficacy and safety of low laser therapy to treat the xerostomia of patients with primary Sjogren's Syndrome.
- Conditions
- KERATOCONJUNCTIVITIS SICCA, XEROSTOMIA, SICCA SYNDROME, PRIMARY SJOGREN SYNDROME
- Trial name
- NCT02066896
- Testing
- Lasertherapy
- Where
- Brazil
- Volunteers
- 66 people
- Sponsor
- Federal University of São Paulo
Bacterial Conjunctivitis
An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% ((VIGAMOX®) Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients
The purpose of this study is to evaluate Moxifloxacin 0.5% relative to Ofloxacin 0.3% in the treatment of bacterial conjunctivitis in Chinese patients.
- Trial name
- NCT01573910
- Testing
- Moxifloxacin ophthalmic solution, 0.5%, Ofloxacin ophthalmic solution, 0.3%
- Where
- China
- Volunteers
- 985 people
- Sponsor
- Alcon Research
Bacterial Conjunctivitis
Safety and Efficacy of Vancomycin Ophthalmic Ointment in Patients With Moderate to Severe Bacterial Conjunctivitis
This is a Phase 3 study to evaluate the safety and efficacy of a vancomycin hydrochloride ophthalmic ointment dosed 4 times daily for 7 days compared to placebo (vehicle) in patients with moderate to severed Gram-positive…
- Trial name
- NCT02432807
- Testing
- Vancomycin 1.1%
- Where
- 16 sites in United States
- Volunteers
- 303 people
- Sponsor
- Kurobe LLC
Acute Bacterial Conjunctivitis
A Study to Determine if 0.6% ISV-403 is Safe and Effective in the Treatment of Bacterial Conjunctivitis.
Evaluation of the clinical and microbial efficacy of 0.6% ISV-403, compared to vehicle in the treatment of bacterial conjunctivitis.
- Trial name
- NCT00347932
- Testing
- ISV-403, Vehicle
- Volunteers
- 957 people
- Sponsor
- Bausch & Lomb Incorporated
Keratoconjunctivitis Sicca
Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca
This is a Phase 2, randomized, double-masked, placebo-controlled, parallel-group study in adult males and females, aged 18 years and over, with a diagnosis of moderate-to-severe keratoconjunctivitis sicca (KCS).
- Trial name
- NCT00349466
- Testing
- CF101
- Where
- 3 sites in Israel
- Volunteers
- 80 people
- Sponsor
- Can-Fite BioPharma
Acute Bacterial Conjunctivitis
Trial to Evaluate the Efficacy and Safety of IVIEW-1201 in Acute Bacterial Conjunctivitis
A Phase 2, Multi-center, Randomized, Parallel Controlled Study to Evaluate the Clinical Efficacy and Safety of IVIEW-1201 (1.0% Povidone-Iodine) Gel Forming Ophthalmic Solution Compared to Ofloxacin Eye Drops in the Treatment of…
- Trial name
- NCT05816070
- Testing
- IVIEW-1201, Ofloxacin Eye Drops
- Where
- China
- Volunteers
- 129 people
- Sponsor
- IVIEW Therapeutics Inc.
Dry Eye Syndrome, Keratoconjunctivitis Sicca
Acute Tear Production Following Single Use of the Oculeve Intranasal Neurostimulator
The primary objective of this study is to evaluate acute tear production as measured by tear meniscus height (TMH) captured by optical coherence tomography (OCT) after single use of the Oculeve Intranasal Neurostimulator (OIN) in…
- Trial name
- NCT02798289
- Testing
- Oculeve Intranasal Neurostimulator
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Oculeve, Inc.
Dry Eye Syndromes, Keratoconjunctivitis Sicca
Six Month Study to Evaluate the Safety and Effectiveness of the Intranasal Lacrimal Neurostimulator
In this study, the safety and effectiveness of the Oculeve Intranasal Lacrimal Neurostimulator after 180 days of use in participants with aqueous tear deficiency will be evaluated.
- Trial name
- NCT02526290
- Testing
- Intranasal Lacrimal Neurostimulator (Oculeve)
- Where
- 3 sites in United States
- Volunteers
- 97 people
- Sponsor
- Oculeve, Inc.
Conjunctivitis, Allergic
A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis
This study will evaluate the duration of action of LASTACAFT® and Pataday™ as compared to artificial tears (placebo) in the prevention of ocular itching associated with allergic conjunctivitis.
- Trial name
- NCT01470118
- Testing
- alcaftadine 0.25% ophthalmic solution, olopatadine 0.2% ophthalmic solution, dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
- Where
- United States
- Volunteers
- 127 people
- Sponsor
- Allergan
Bacterial Conjunctivitis
Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004)
The purpose of this study is to evaluate the clinical and microbial efficacy and safety of AzaSite compared to tobramycin for bacterial conjunctivitis.
- Trial name
- NCT00105469
- Testing
- AzaSite, Tobramycin
- Where
- 26 sites in United States
- Volunteers
- 743 people
- Sponsor
- Merck Sharp & Dohme LLC
Dry Eye, Kerato Conjunctivitis Sicca
A Study Evaluating the Safety of the Nasal Pump
The objective of this study is to determine the safety of the Tyrvaya nasal pump.
- Trial name
- NCT06329687
- Testing
- Tyrvaya Nasal Pump
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Oyster Point Pharma, Inc.
Allergic Conjunctivitis
Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis
The purpose of the study is to demonstrate safety and efficacy of DE-114 ophthalmic solution compared to its Placebo and Olopatadine hydrochloride 0.1% ophthalmic solution in patients with allergic conjunctivitis.
- Trial name
- NCT01363700
- Testing
- DE-114 ophthalmic solution, Olopatadine Hydrochloride 0.1% Ophthalmic Solution
- Where
- Japan
- Volunteers
- 87 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Allergic Conjunctivitis
A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC)
The purpose of this study is to evaluate the onset and duration of action of AC-170 0.24% compared to vehicle in the prevention of the signs and symptoms of allergic conjunctivitis in the conjunctival allergen challenge (CAC)…
- Trial name
- NCT01551056
- Testing
- AC-170 0.24%, AC-170 0%
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Aciex Therapeutics, Inc.
Conjunctivitis, Bacterial
Efficacy of the Ophthalmic Pazufloxacin 0.6% for Bacterial Conjunctivitis, Compared to Gatifloxacin 0.3%.
Phase III clinical study of non-inferiority, multicenter, double-blind, with comparative group, of parallel groups and randomized. about a ophthalmic topical antibiotic for the treatment of bacterial conjunctivitis.
- Trial name
- PRO-157 (NCT03696342)
- Testing
- Pazufloxacin, Zymar
- Where
- 6 sites in Mexico
- Volunteers
- 46 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Allergic Conjunctivitis
Confocal Analysis of Corneal Structures of Symptomatic Allergic Conjunctivitis Patients
The purpose of this study is to descriptively evaluate the corneal structures of allergic conjunctivitis patients.
- Trial name
- NCT01697969
- Testing
- Olopatadine hydrochloride ophthalmic solution, 0.2%
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Alcon Research
Conjunctivitis, Allergic
A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis
This study will evaluate the efficacy of Lastacaft® (Alcaftadine 0.25%) and Pataday™ (Olopatadine 0.2%) as compared to each other and to placebo in the prevention of ocular itching associated with allergic conjunctivitis.
- Trial name
- NCT01732757
- Testing
- Alcaftadine 0.25%, Olopatadine 0.2%, dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%
- Where
- United States
- Volunteers
- 157 people
- Sponsor
- Allergan
Keratoconjunctivitis Sicca
A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome (DES)
The purpose of this study is to evaluate whether SkQ1 ophthalmic solutions are safe and effective compared to placebo for the treatment of the signs and symptoms of dry eye syndrome.
- Trial name
- NCT02121301
- Testing
- Low Dose 0.155µg/mL SkQ1 ophthalmic solution, High Dose 1.55µg/mL SkQ1 ophthalmic solution
- Where
- United States
- Volunteers
- 91 people
- Sponsor
- Mitotech, SA
Chronic Allergic Conjunctivitis
OTX-15-002: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-DP for the Treatment of Chronic Allergic Conjunctivitis
The objective of the study was to evaluate the efficacy and safety of OTX-DP (dexamethasone insert) 0.4 mg for intracanalicular use when placed in the canaliculus of the eyelid for the treatment of the signs and symptoms of…
- Trial name
- NCT02988882
- Testing
- Dexamethasone
- Volunteers
- 86 people
- Sponsor
- Ocular Therapeutix, Inc.
Bacterial Conjunctivitis
Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin)
A randomized, double blind, phase II multicenter trial with the objective of assess the safety and efficacy of the PRO-157 ophthalmic solution in three different dosing regimens, versus Moxifloxacin, versus Gatifloxacin in…
- Trial name
- Pazufloxacin (NCT02980523)
- Testing
- PRO-157, Vigamox, Zymar®
- Where
- Mexico
- Volunteers
- 150 people
- Sponsor
- Laboratorios Sophia S.A de C.V.